DaVita (NYSE:DVA) Shares Gap Down – Time to Sell?

DaVita Inc. (NYSE:DVA)’s stock price gapped down prior to trading on Friday. The stock had previously closed at $193.31, but opened at $175.00. DaVita shares last traded at $178.84, with a volume of 362,231 shares trading hands.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported third-quarter revenue of $3.578 billion, up 4.6% year over year and ahead of the approximately $3.52 billion analyst estimate. Adjusted earnings per share were $3.82, above the $3.57 consensus, while earnings increased substantially from $2.51 a year earlier. DaVita Q3 revenue report
• Positive Sentiment: Net income attributable to common shareholders rose 48.3% year over year to $222.9 million. The results indicate continued revenue growth and improved earnings power, supporting the company’s full-year outlook and valuation case. DaVita Q3 2026 earnings summary
• Neutral Sentiment: Cash flow from operations declined to $518.8 million, while capital expenditures totaled $159.5 million. Operating profit also slipped 1.3% year over year to $499.3 million, suggesting that revenue growth has not fully translated into stronger underlying operations. DaVita third-quarter 2026 results
• Negative Sentiment: A roughly $62 million charge related to DaVita’s China operations overshadowed the earnings beat and raised concerns about international execution and near-term profitability. This was the primary reason investors sold the stock following the report. DaVita Q3 earnings and China charge
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of DaVita investors. Although the announcement does not establish wrongdoing, the legal overhang may add uncertainty and weigh on investor sentiment. Pomerantz DaVita investor investigation

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 price objective on shares of DaVita in a report on Wednesday, August 5th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Barclays lifted their price target on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Raymond James Financial set a $220.00 price objective on DaVita in a report on Friday, August 7th. Finally, Truist Financial cut their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Trading Down 7.0%

The stock’s 50 day moving average is $181.13 and its 200 day moving average is $176.11. The stock has a market capitalization of $11.47 billion, a price-to-earnings ratio of 14.72, a PEG ratio of 0.48 and a beta of 0.80.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, October 29th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.57 by $0.25. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.58 billion during the quarter, compared to analysts’ expectations of $3.52 billion. During the same quarter in the previous year, the business posted $2.51 earnings per share. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. On average, sell-side analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

Institutional Investors Weigh In On DaVita

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Value Investment Professionals LLC increased its position in DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after buying an additional 50 shares in the last quarter. Kesler Norman & Wride LLC raised its holdings in shares of DaVita by 0.8% in the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after acquiring an additional 55 shares during the last quarter. State of Alaska Department of Revenue lifted its position in shares of DaVita by 1.9% in the third quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company’s stock valued at $560,000 after acquiring an additional 60 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of DaVita by 4.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock valued at $426,000 after acquiring an additional 76 shares in the last quarter. Finally, CoreCap Advisors LLC boosted its stake in shares of DaVita by 161.7% during the third quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock valued at $27,000 after acquiring an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.